Rafael Amado
Overview
Rafael Amado received an average of $7M in total compensation, including $409K in salary, at Allogene Therapeutics from 2019 to 2021. Rafael Amado also received an average of $2M at Adaptimmune Therapeutics from 2015 to 2018.
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
Allogene TherapeuticsChief Medical Officer and Executive Vice President of Research and Development
Allogene TherapeuticsChief Medical Officer and Executive Vice President of Research and Development
Allogene TherapeuticsChief Medical Officer and Executive Vice President of Research and Development
Adaptimmune TherapeuticsPresident, Research & Development
Adaptimmune TherapeuticsChief Medical Officer
Adaptimmune TherapeuticsChief Medical Officer
Adaptimmune TherapeuticsChief Medical Officer
Source: SEC filings on April 26, 2022, April 22, 2021, April 23, 2020, March 15, 2019, April 27, 2018, and April 28, 2017.
Related executives
We found 11 more executives who work or worked at Allogene Therapeutics and Adaptimmune Therapeutics.
David Chang
Allogene Therapeutics
Chief Executive Officer
Adrian Rawcliffe
Adaptimmune Therapeutics
Chief Executive Officer
Alison Moore
Allogene Therapeutics
Chief Technical Officer
Eric Schmidt
Allogene Therapeutics
Chief Financial Officer
Veer Bhavnagri
Allogene Therapeutics
General Counsel
Helen Tayton-Martin
Adaptimmune Therapeutics
Chief Business Officer
William Bertrand
Adaptimmune Therapeutics
Chief Operating Officer
Gavin Wood
Adaptimmune Therapeutics
Chief Financial Officer
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019